New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants

As new, efficacious respiratory syncytial virus (RSV) immunization products reach the market, affordable pricing as well as improved estimation of disease burden and the full potential and cost effectiveness of RSV prevention in the hardest hit geographies in low- and middle-income countries are cri...

Descripción completa

Detalles Bibliográficos
Autores principales: Srikantiah, Padmini, Klugman, Keith P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184394/
https://www.ncbi.nlm.nih.gov/pubmed/37183242
http://dx.doi.org/10.1186/s12916-023-02883-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184394/
https://www.ncbi.nlm.nih.gov/pubmed/37183242
http://dx.doi.org/10.1186/s12916-023-02883-x

Ejemplares similares